258 related articles for article (PubMed ID: 14739769)
1. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.
Peterson JT
Heart Fail Rev; 2004 Jan; 9(1):63-79. PubMed ID: 14739769
[TBL] [Abstract][Full Text] [Related]
2. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
3. MMP inhibitors in cardiac diseases: an update.
Dormán G; Kocsis-Szommer K; Spadoni C; Ferdinandy P
Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):186-94. PubMed ID: 18221118
[TBL] [Abstract][Full Text] [Related]
4. The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors.
Peterson JT
Cardiovasc Res; 2006 Feb; 69(3):677-87. PubMed ID: 16413004
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase inhibitors reduce collagen gel contraction and alpha-smooth muscle actin expression by periodontal ligament cells.
Bildt MM; Bloemen M; Kuijpers-Jagtman AM; Von den Hoff JW
J Periodontal Res; 2009 Apr; 44(2):266-74. PubMed ID: 18973523
[TBL] [Abstract][Full Text] [Related]
7. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
Pauschinger M; Chandrasekharan K; Schultheiss HP
Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs.
Jabłońska-Trypuć A; Matejczyk M; Rosochacki S
J Enzyme Inhib Med Chem; 2016; 31(sup1):177-183. PubMed ID: 27028474
[TBL] [Abstract][Full Text] [Related]
10. [Doxycycline or how to create new with the old?].
Shehwaro N; Langlois AL; Gueutin V; Gauthier M; Casenave M; Izzedine H
Therapie; 2014; 69(2):129-41. PubMed ID: 24926631
[TBL] [Abstract][Full Text] [Related]
11. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
12. [Comparison of doxycycline, losartan, and their combination on the expression of matrix metalloproteinase, tissue inhibitor of matrix metalloproteinase, and collagen remodeling in the noninfarcted myocardium after acute myocardial infarction in rats].
Zhang P; Yang YJ; Chen X; Ruan YM; Zhou YW; Tian Y; Chen ZJ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Feb; 27(1):53-61. PubMed ID: 15782494
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases, tissue inhibitor of matrix metalloproteinase-1, and laminin-5 gamma2 chain immunolocalization in gingival tissue of endotoxin-induced periodontitis in rats: effects of low-dose doxycycline and alendronate.
Buduneli E; Vardar-Sengül S; Buduneli N; Atilla G; Wahlgren J; Sorsa T
J Periodontol; 2007 Jan; 78(1):127-34. PubMed ID: 17199549
[TBL] [Abstract][Full Text] [Related]
14. Effect of matrix metalloproteinase inhibition by doxycycline on myocardial healing and remodeling after myocardial infarction.
Tessone A; Feinberg MS; Barbash IM; Reich R; Holbova R; Richmann M; Mardor Y; Leor J
Cardiovasc Drugs Ther; 2005 Dec; 19(6):383-90. PubMed ID: 16435072
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
Li NG; Tang YP; Duan JA; Shi ZH
Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases and periodontal diseases.
Sapna G; Gokul S; Bagri-Manjrekar K
Oral Dis; 2014 Sep; 20(6):538-50. PubMed ID: 23849049
[TBL] [Abstract][Full Text] [Related]
17. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate.
Teronen O; Konttinen YT; Lindqvist C; Salo T; Ingman T; Lauhio A; Ding Y; Santavirta S; Sorsa T
J Dent Res; 1997 Sep; 76(9):1529-37. PubMed ID: 9294486
[TBL] [Abstract][Full Text] [Related]
18. Introduction and background.
Golub LM
Pharmacol Res; 2011 Feb; 63(2):99-101. PubMed ID: 20937387
[TBL] [Abstract][Full Text] [Related]
19. Selective matrix metalloproteinase inhibitors for cancer.
Lia NG; Shib ZH; Tang YP; Duan JA
Curr Med Chem; 2009; 16(29):3805-27. PubMed ID: 19747139
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid.
Srinivas R; Sorsa T; Tjäderhane L; Niemi E; Raustia A; Pernu H; Teronen O; Salo T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 May; 91(5):517-25. PubMed ID: 11346728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
